FEB 25, 2019 03:40 PM PST

Open-Science Model Advances Drug Discovery

WRITTEN BY: Nouran Amin

Parkinson’s disease and Amyotrophic Lateral Sclerosis is the latest push for Medicines 4 Neurodegenerative Diseases (M4ND Pharma) by academic scientists in Toronto in their promising pursuit for a new genetic drug that targets intractable nervous system disorders. Thanks to funding from the Krembil Foundation, M4ND Pharma will be the world's second drug discovery company dedicated to open science after Medicines 4 Kids (M4K Pharma). Similar to M4K Pharma, M4D will not seek patents on its findings but will instead rely on regulations regarding data exclusivity for the reasons of supporting the open science movement.

In open science, researchers can share resources and exchange knowledge without limitations due to patents and the peer review publishing process. The aim of open science is to advance scientific discovery—it was the same movement that garnered the Human Genome Project, and the non-profit Structural Genomics Consortium (SGC).

"When we started M4K, many people thought an open approach to late-stage drug development might only be applicable to rare or neglected diseases, if at all," says Aled Edwards, a professor of molecular genetics at the University of Toronto and CEO of the SGC. "But we're getting unexpected funding and scientific contributions from industry, academic and clinical sources, and slowly but surely we're advancing a medicine through the pipeline. It's time to move the goal posts again on what's possible with open science."

Learn more about open science:

fordable medicines faster, but it's been incredibly challenging to make it happen because the system is complicated," says Edwards. "The key was to invent a different business model, and we're extraordinarily happy that industry, academia and others have been delighted to contribute."

Source: University of Toronto

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 15, 2018
Drug Discovery
NOV 15, 2018
Anti-inflammatory Drug Works Like an Inhibitor
At Karolinska Institutet in Sweden, a team of scientists from multiple disciplines have worked together to develop an inflammation inhibitor. The new anti-...
DEC 06, 2018
Drug Discovery
DEC 06, 2018
Repurposing Cancer Drugs For HPV Treatment
Drug repurposing is transforming the health care world. The idea that old, previously-- FDA approved drugs could be altered and to be used again for the tr...
DEC 17, 2018
Health & Medicine
DEC 17, 2018
Light Makes An Itch Go Away!
EMBL researchers have now found a way to stop itch with light in mice. Nature Biomedical Engineering publishes their results on 17 December 2018....
JAN 03, 2019
Health & Medicine
JAN 03, 2019
Antibiotic Resistance - A Global Health Threat
Antibiotics play a critical role in fighting off bacterial infections. Since the discovery of the first antibiotic, Penicillin, antibiotic treatment became an effective and safe tool which is...
FEB 11, 2019
Chemistry & Physics
FEB 11, 2019
Actinium-based Targeted Alpha Therapy Delivers A Combo Punch
Radiotherapy is a staple among many medical interventions to treat cancer. Besides external beam radiotherapy and sealed radio-source therapy, it is common...
FEB 17, 2019
Drug Discovery
FEB 17, 2019
Drug Combination May Become Standard Treatment for Metastatic Kidney Cancer
Reporting from results of a phase 3 clinical trial, patients with metastatic kidney cancer may soon receive a new standard treatment involving a combinatio...
Loading Comments...